Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease

J. Lukas, B. Hintnausova, V. Sykorova, M. Syrucek, M. Maly, D. Lukas, J. Duskova

. 2025 ; 169 (1) : 26-31. [pub] 20231206

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008983

BACKGROUND: The current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy. METHODS: Prospectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules. RESULTS: Preoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively). CONCLUSIONS: Our experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008983
003      
CZ-PrNML
005      
20250521143018.0
007      
ta
008      
250411s2025 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.048 $2 doi
035    __
$a (PubMed)38058193
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lukáš, Jindřich $u Department of Otolaryngology - Head and Neck Surgery, Na Homolce Hospital, Prague, Czech Republic $u Ear, Nose, and Throat Department Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic $7 mzk2005269599
245    10
$a Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease / $c J. Lukas, B. Hintnausova, V. Sykorova, M. Syrucek, M. Maly, D. Lukas, J. Duskova
520    9_
$a BACKGROUND: The current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy. METHODS: Prospectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules. RESULTS: Preoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively). CONCLUSIONS: Our experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.
650    _2
$a lidé $7 D006801
650    12
$a uzly štítné žlázy $x genetika $x patologie $7 D016606
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    12
$a nádory štítné žlázy $x genetika $7 D013964
650    _2
$a senioři $7 D000368
650    _2
$a tenkojehlová biopsie $7 D044963
650    _2
$a rizikové faktory $7 D012307
650    _2
$a genetické testování $7 D005820
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hintnausová, Barbora $u Department of Internal Medicine, Endocrinology Centre, Na Homolce Hospital, Prague, Czech Republic $7 xx0230501
700    1_
$a Sýkorová, Vlasta $u Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic $7 xx0118026
700    1_
$a Syrůček, Martin $u Department of Pathology, Na Homolce Hospital, Prague, Czech Republic $7 xx0145890
700    1_
$a Malý, Marek, $d 1961- $u Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic $7 jn20001103265
700    1_
$a Lukáš, David $u Department of General Surgery, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 _AN052899
700    1_
$a Dušková, Jaroslava, $d 1952- $u Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 jo2002104714
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 169, č. 1 (2025), s. 26-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38058193 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20250411 $b ABA008
991    __
$a 20250521143016 $b ABA008
999    __
$a ok $b bmc $g 2324859 $s 1246061
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 169 $c 1 $d 26-31 $e 20231206 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20250411

Najít záznam

Citační ukazatele

Možnosti archivace